Hepatic fibrosis, which is important risk factor in the prognosis of NAFLD patients is related not only to traditional TGF-β pathway, but also FOSL2, ADAM17, and angiotensin pathway (24–26). Here, FOSL2 is linked to metabolic dysfunction-associated steatotic liver disease.